there are still 20%-40% ccRCC patients developing local recurrence or distant metastasis after surgery. 2, 4 Hence, investigation of additional biomarkers to supervise disease development and progression is imperative in ccRCC patients.
Integrins, one family of cell adhesion molecules, are heterodimers consisting of an alpha and a beta subunit, which play important roles in many physiological and pathological processes via regulating cell-cell or cell-matrix adhesion. 5 Integrin α7, belonging to the integrin family of adhesion molecule, is localized on chromosome 12p13 and consists of at least 27 exons spanning a region of about 22.5 kb. 6 According to accumulating evidences, integrin α7 serves as an important regulator in tumor progression of several carcinomas, including prostate cancer, esophageal squamous cell carcinoma (OSCC), and glioblastoma. [5] [6] [7] [8] In addition, integrin α7 also has been described as a functional cancer stem cells (CSCs) surface marker, and its knockdown could effectively decrease the stemness of cancer cells, such as OSCC, whereas the information about the role of integrin α7 in RCC, particular in ccRCC, is still rarely known. 6 Considering the key role of integrin α7 in tumor progression and its effect on CSC properties in different carcinomas, we hypothesized that integrin α7 might play a critical role in ccRCC.
Thus, this study aimed to explore the association of integrin α7 with clinicopathological characteristics and overall survival (OS) in ccRCC patients. 
| MATERIAL S AND ME THODS

| Patients
| Tissue specimens and data collection
Tumor tissue and paired adjacent tissue specimens of patients were obtained from Tumor Specimen storeroom of hospital.
Baseline characteristics of patients were collected from medical records, which included age, gender, tumor location, pathological grade, tumor size, T stage, N stage, and TNM stage. In addition, survival data were also collected from patients' follow-up records, and the median follow-up duration was 91.0 months (range: 3.0-116.0 months).
| Immunohistochemistry assay
Firstly, formalin-fixed and paraffin-embedded specimens of tumor tissue and paired adjacent tissue were serially sectioned at 4 μm thickness, and the sections were deparaffinized with xylene, rehydrated with ethanol, microwaved in 0.01 mol/L sodium citrate buffer (pH 6.0) for antigen retrieval, and incubated with H 2 O 2 at 37°C for and proportion score were used to calculate the total score. Two investigators blinded to the type of tissues performed these procedures. For staining in tumor tissue and paired adjacent tissue, it was visually scored and quantified according to a semiquantitative scoring system. 9 Briefly, the intensity of immunostaining was scored as: 0 = negative (no staining), 1 = weak (light yellow), 2 = moderate (yellow), and 3 = strong (brown); and the proportion of immune-positive cells was scored as: 1 = <10%, 2 = 10% ~ 50%, 3 = 51% ~ 75%, and 4 = more than 75%. The two scores of the corresponding sample were multiplied to obtain a total score ranging from 0 to 12 points.
High expression of integrin α7 was defined as total score ≥3, and low expression of integrin α7 was defined as total score <3. All procedures in this experiment were performed by one specialist from the Laboratory Department of our hospital who were blinded to the type of tissues and patients' information. In addition, the IHC was scored by two clinic pathologists with rich experience from the Pathological Department of our hospital who were blinded to the type of tissues and patients' information as well. When the opinion of these two clinic pathologists was different, the third clinic pathologist with rich experience from the Pathological Department of our hospital who were blinded to the type of tissues and patients' information would score the results of IHC.
| Statistical analysis
Statistical analysis was performed by SPSS 19.0 software (IBM), and graph making was accomplished using GraphPad Prism 7.00 (GraphPad Inc). Normal distributed continuous variables were presented as mean value ± standard deviation; skewed distributed continuous variables were presented as median (25th-75th quantiles); and categorized variables were presented as count 
| RE SULTS
| Study flow
A total of 415 patients with RCC who underwent nephrectomy were screened, while 204 cases were excluded, among which 79 cases were with tissue samples unavailable, 65 cases were without complete medical records or follow-up data, 31 cases were with other types of RCC other than ccRCC, 18 cases were with TNM stage IV or distant metastasis, seven cases had a history of malignant tumors other than ccRCC, and four cases were with secondary ccRCC (Figure 1 ). Subsequently, 211 ccRCC cases were eligible, whereas 32 cases were excluded, including 28 cases who could not be contacted to get informed consents and four cases who were reluctant to provide the written informed consents. Finally, the remaining 179 ccRCC cases were included in the analysis.
| Baseline characteristics
The mean age of 179 included ccRCC patients was 59.8 ± 12.3 years, and there were 102 male (57.0%) and 77 females (43.0%; Table 1 ).
The number of patients with pathological grade 1, 2, and 3 was 79 (44.1%), 78 (43.6%), and 22 (12.3%), respectively. The median tumor size was 5.0 (4.0-7.5) cm. In addition, 125 (69.8%), 36 (20.1%), and 18 (10.1%) patients were with TNM stage I, II, and III. Other characteristics were shown in Table 1 . semiquantitative scoring were shown in Figure 2A . Most importantly, integrin α7 expression was observed to be increasingly expressed in tumor tissue compared to paired adjacent tissue (P < .001; Figure 2B ).
| Expression of integrin α7 in tumor tissue and paired adjacent tissue
| Association of tumor integrin α7 expression with tumor characteristics
Tumor integrin α7 high expression was correlated with higher pathological grade (P = .004), increased T stage (P = .017), and advanced TNM stage (P = .033; Table 2 ). However, no correlation was found between tumor integrin α7 expression and other characteristics (All P > .05).
F I G U R E 2
Integrin α7 expression between tumor tissue and adjacent tissue. Immunohistochemistry assay revealed that integrin α7 was highly expressed in tumor tissue (A). The percentage of patients with integrin α7 high expression in tumor tissue was increased than that in adjacent tissue (B (Figure 3 ). Tumor integrin α7 high expression was correlated with worse OS in ccRCC patients (P < .001).
| Factors influencing OS in ccRCC patients
Univariate Cox's regression revealed that tumor integrin α7 high expression (P < .001), age (>60 years vs ≤60 years; P = .001), higher pathological grade (P < .001), tumor size (>5 cm vs ≤5 cm; P = .006), higher T stage(P < .001), N stage (1 vs 0; P < .001), and higher TNM stage (P < .001) were associated with shorter OS (Table 3 ). Multivariate Cox's regression with Forward Stepwise (Conditional) method was further performed, which disclosed that tumor integrin α7 high expression (P < .001), higher pathological grade (P < .001), and higher TNM stage (P < .001) could independently predict poor OS in ccRCC patients.
| D ISCUSS I ON
In the present study, we observed that (1) Integrin α7 was highly expressed in tumor tissue, and its high expression was associated with advanced cancer features. (2) Tumor integrin α7 high expression independently predicted poor OS in ccRCC patients.
Integrin α7, a member of the extracellular matrix binding proteins, contributes to the interaction of relevant cell-cell and cell-extracellular matrix in a wide range of cellular processes, which also involves in the processes of tumorigenesis and tumor progression in different malignancies. 5, 7 A majority of previous studies have focused on the function of integrin α7 on cell activities in different carcinomas and disclosed its tumor promoter role in these cancers. For example, integrin α7 interacts with S100P to promote cells migration and cells invasion in lung carcinoma. 10 Another mechanistic study discloses that integrin α7 induces cells migration and invasion abilities via the activation of epithelial-mesenchymal transition (EMT) in OSCC. 6 In addition, parts of previous studies have revealed that integrin α7 possesses effect on regulating stemness of cancer cells. For instance, integrin α7 effectively promotes the stemness of OSCC cells through regulating the focal adhesion kinase (FAK)-mediated pathway in OSCC. 6 Therefore, these previous evidences suggest that integrin α7 appears to be a promoter in the pathological processes of several carcinomas due to its effect on cell activities and stemness of cancer cells.
In clinical trials, there is limited information about the association of integrin α7 with disease conditions in carcinomas, among which one previous study reveals that integrin α7 is related to poor differentiation and lymph node metastasis in OSCC patients, while little is known about the participation of integrin α7 in RCC patients, particularly ccRCC patients. 6 In consideration of the underlying mechanism and influence of integrin α7 in different carcinomas as well as its correlation with the stemness of cancer cells, we suspected that integrin α7 might exert an influence on tumor progression in ccRCC patients. Thus, we evaluated the association of integrin α7 with clinicopatholgocial features in ccRCC patients, and we found that integrin α7 was highly expressed in tumor tissue, and its high expression was associated with patients. 6, 7, 11, 12 Therefore, there are controversial results related to the prognostic value of integrin α7 in patients with different carcinoma, which might be caused by different inclusion and exclusion criteria or different sample size and its function in different carcinomas. In the present study, we discovered that integrin α7 could independently predict shorter OS in ccRCC patients. The possible reasons were as follows: (a) Integrin α7 devoted in the exacerbation of disease conditions through increasing tumor growth and metastasis by mediating some pathways (such as EMT pathway), thereby led to shorter survival in ccRCC patients. (b) Integrin α7 might regulate multiple pathways (including the corresponding FAK/MAPK/ ERK pathway) to increase stemness of cancer cells, subsequently enhancing the abilities to self-renew, differentiate and chemoresistance, which caused poor survival in ccRCC patients.
Although some interesting results were discovered in this study, some limitations still existed. Firstly, this is a retrospective study, and we screened all patients who had completed records regarding OS, but not DFS, and the effect of integrin α7 on DFS in ccRCC patients was not investigated due to the loss of DFS records. Secondly, the sample size in this study was relatively small, which might cause poor statistical power. Thirdly, all patients enrolled in this study were from our hospital, which might result in regional bias.
In a word, integrin α7 is upregulated in tumor tissue, and it correlates with higher pathological grade, increased T stage, and advanced TNM stage; meanwhile, it also acts as a valuable prognostic factor for worse survival in ccRCC patients.
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